Mental health

EMA's safety committee has opened a Deanxit safety review at Belgium's request, after reports of movement disorders and memory problems with the flupentixol/melitracen combination. The Belgian agency also questioned the benefit of combining the two substances. #SyenzaNews #Pharmacovigilance #EMA #MentalHealth

Infarmed's first Deep Dive looks at migraine medicines in Portugal. In 2025, more than 73,000 people used SNS-reimbursed migraine therapies, 85% of them women. Patients paid about €6 million (61%) of the €9.9 million pharmacy bill, and atogepant, funded only at the end of 2024, already led spending. #SyenzaNews #Migraine #MarketAccess #Portugal

The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer's Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess

Reinforcement learning rTMS for depression: a new npj Digital Medicine study tests protocol recommendations against clinician choices in 1,609 adults.

Social prescribing is not yet part of Portugal's national health system. Economists are asking whether it works, and who pays for it.

A randomized trial in 268 men awaiting radical prostatectomy found AI preoperative communication cut GAD-7 anxiety scores and nearly halved surgeon consultation time. The AI answered 2,847 of 3,507 patient questions. #SyenzaAI #SyenzaNews #MarketAccess #ProstateCancer #AIinHealthcare

EMEA and GBEI brought China, Malaysia, Japan and India together to map an Asian brain economy strategy, framing brain capital as core economic infrastructure and introducing the Asian Brain Economy Index. #BrainEconomy #BrainCapital #Asia #BrainHealth

Definium Therapeutics' DT120 ODT met its primary endpoint in the Phase 3 Panorama trial, delivering a 5.1-point placebo-adjusted improvement on the HAM-A anxiety scale. #SyenzaNews #GAD #MentalHealth #MarketAccess

The FDA's landmark hearing on psychedelic medicines drew 80 speakers and 1,800 registrants, and the market access message was clear: approval is not access, and reimbursement is the binding constraint. #SyenzaNews #MarketAccess #Psychedelics #HealthPolicy

🧬 Could your gut microbiota reveal clues about psychopathic traits? New research highlights how distinct microbial profiles may serve as biomarkers, opening fresh paths for mental health diagnostics and targeted interventions in psychiatry. Explore the study’s implications for precision approaches to behavioral health. #SyenzaNews #biotechnology #precisionmedicine #innovation

Could data-driven care pathways transform treatment for major depressive disorder? 🧠 This article outlines how treatment-pathway modeling uses patient data and simulation to identify optimal sequencing, improve remission rates, and guide resource allocation—balancing clinical outcomes with economic impact. It highlights practical implications for clinicians, payers, and policymakers seeking more personalized, cost-effective MDD care. Read the full analysis to explore the models, key findings, and next steps for implementation. #SyenzaNews #AIinHealthcare #HealthTech #innovation #costeffectiveness

Can evidence-based guidelines reduce unnecessary dementia medications while improving quality of care? 🧠 The Dutch guidance emphasizes prioritizing non‑pharmacological interventions, clearer criteria for initiating or deprescribing antipsychotics and cognitive enhancers, and stronger person‑centered, multidisciplinary support for patients and caregivers. Read the full article to explore the practical recommendations and what they mean for clinicians, caregivers, and policymakers. #SyenzaNews #healthcare #HealthcareInnovation #healthcarepolicy #innovation